ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Genelux Corporation

Genelux Corporation (GNLX)

2.28
-0.09
( -3.80% )
Updated: 11:06:00

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
2.28
Bid
2.28
Ask
2.30
Volume
34,761
2.27 Day's Range 2.45
1.60 52 Week Range 30.44
Market Cap
Previous Close
2.37
Open
2.33
Last Trade
24
@
2.29
Last Trade Time
11:06:22
Financial Volume
$ 81,087
VWAP
2.3327
Average Volume (3m)
210,157
Shares Outstanding
34,535,471
Dividend Yield
-
PE Ratio
-2.82
Earnings Per Share (EPS)
-0.82
Revenue
170k
Net Profit
-28.3M

About Genelux Corporation

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac... Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
-
Genelux Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GNLX. The last closing price for Genelux was $2.37. Over the last year, Genelux shares have traded in a share price range of $ 1.60 to $ 30.44.

Genelux currently has 34,535,471 shares outstanding. The market capitalization of Genelux is $81.85 million. Genelux has a price to earnings ratio (PE ratio) of -2.82.

GNLX Latest News

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.38-14.28571428572.662.832.271447922.47715163CS
40.115.069124423962.173.111.952013712.45494102CS
120.062.70270270272.223.111.62101572.19230565CS
26-3.58-61.09215017065.866.51.62118692.81633852CS
52-25.66-91.839656406627.9430.441.61764687.3136082CS
156-3.72-62640.981.615579212.0897135CS
260-3.72-62640.981.615579212.0897135CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
XPONExpion360 Inc
$ 0.194
(233.33%)
933.75M
BNZIBanzai International Inc
$ 6.60
(129.17%)
45.28M
LFLYLeafly Holdings Inc
$ 2.805
(56.70%)
23.3M
VERBVerb Technology Company Inc
$ 0.0796
(43.17%)
115.96M
GLMDGalmed Pharmaceuticals Ltd
$ 10.36
(23.33%)
12.05M
GSIWGarden Stage Ltd
$ 3.05
(-61.05%)
5.53M
LGCBLinkage Global Inc
$ 0.4028
(-59.26%)
1.3M
CRBPCorbus Pharmaceuticals Holdings Inc
$ 21.68
(-58.07%)
6.97M
SKYESkye Bioscience Inc
$ 2.99
(-45.54%)
1.53M
KOPNKopin Corporation
$ 0.65
(-32.58%)
6.35M
XPONExpion360 Inc
$ 0.1935
(232.47%)
933.08M
VERBVerb Technology Company Inc
$ 0.0796
(43.17%)
115.96M
NVDANVIDIA Corporation
$ 116.25
(-1.37%)
99.64M
HOLOMicroCloud Hologram Inc
$ 0.2486
(7.34%)
58.89M
SVMHSRIVARU Holding Ltd
$ 0.1236
(-0.32%)
58.79M

GNLX Discussion

View Posts
tradernewstip tradernewstip 1 week ago
$GNLX Possible Breakout! announcements, and upcoming milestones in a fireside chat at the H.C. Wainwright Global Healthcare Conference, taking place September 9-11, 2024, in New York City, New York. The conversation with Emily Bodnar, Vice President, Equity Research and H.C. Wainwright Biotechnology Analyst, is scheduled to begin at 12:30 p.m. ET on Wednesday, September 11, 2024. A webcast link for the H.C. Wainwright Conference event will be available at https://journey.ct.events/view/d1ba765d-c21b-46c9-8197-e4dd858808f0. An archived replay will be available for approximately 90 days following the event on the company’s IR page.

https://finance.yahoo.com/news/genelux-corporation-present-h-c-200100800.html
πŸ‘οΈ0
tradernewstip tradernewstip 2 weeks ago
$GNLX 1 Month chart resistance in play https://schrts.co/BWBNmgEe
πŸ‘οΈ0
tradernewstip tradernewstip 2 weeks ago
$GNLX Fundamental breakout Volume recovery get in early for the big boom https://schrts.co/sGWIJqyY
πŸ‘οΈ0
Monksdream Monksdream 3 weeks ago
GNLX under $3
πŸ‘οΈ0
tradernewstip tradernewstip 3 weeks ago
Is Genelux (NASDAQ: $GNLX) In A Good Position To Invest In Growth? https://finance.yahoo.com/news/genelux-nasdaq-gnlx-good-position-134334395.html
πŸ‘οΈ0
tradernewstip tradernewstip 1 month ago
$GNLX Technical chart
https://schrts.co/SjVYghqR
πŸ‘οΈ0
tradernewstip tradernewstip 2 months ago
$GNLX Website : https://genelux.com/
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
GNLX under $3
πŸ‘οΈ0
tradernewstip tradernewstip 2 months ago
$GNLX historical movement price and volume https://ih.advfn.com/stock-market/NASDAQ/genelux-GNLX/historical
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
GNLX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
GNLX new 52 lo
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
GNLX new 52 lo
πŸ‘οΈ0
MiamiGent MiamiGent 10 months ago
GNLX Genelux gets fast track status for Olvi-Vec in ovarian cancer
Nov. 27, 2023 3:22 PM ET Genelux Corporation (GNLX) By: Val Brickates Kennedy, SA News Editor

https://stockcharts.com/h-sc/ui?s=GNLX

Genelux (NASDAQ:GNLX) said it has received fast-track status from the FDA for its Olvi-Vec program for the treatment of platinum resistant/refractory ovarian cancer.

The company is currently conducting a Phase 3 registrational study of the immunotherapy in combination with platinum-based chemotherapy in patients with platinum resistant/refractory ovarian cancer.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock